Tipping the balance of cell death: alternative splicing as a source of MCL-1S in cancer
2024
MCL-1S in Cancer: A New Therapeutic Target
publication
10 minutes
Evidence: moderate
Author Information
Author(s): Hartman Mariusz L.
Primary Institution: Medical University of Lodz
Hypothesis
Can alternative splicing of MCL-1 pre-mRNA provide a new therapeutic approach in cancer treatment?
Conclusion
The study suggests that increasing levels of the pro-apoptotic MCL-1S isoform may enhance cancer cell sensitivity to treatment.
Supporting Evidence
- MCL-1S is generated through alternative splicing, specifically via exon skipping.
- MCL-1S acts as a pro-apoptotic protein by binding exclusively to MCL-1L.
- Upregulating MCL-1S by interfering with splicing machinery induces apoptosis in cancer.
Takeaway
MCL-1S is a special protein that helps cancer cells die, and scientists think we can use it to make cancer treatments work better.
Methodology
This review discusses the structure and function of MCL-1S and its potential therapeutic inducers based on existing literature.
Limitations
The review primarily synthesizes existing studies and does not present new experimental data.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website